Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic kicks off Endeavor Resolute studies

This article was originally published in Clinica

Executive Summary

Medtronic's next-generation Endeavor Resolute zotarolimus-eluting stent is to enter two new trials. RESOLUTE US will enrol 1,399 patients and use historical data from other Medtronic stent studies as a control. One of the trial's endpoints is the rate of target lesion failure at one year. Data from the trial will be used to seek FDA approval of the stent. RESOLUTE International will enrol up to 2,200 patients to evaluate the device in a "real-world" population. Its primary endpoint is a composite of cardiac death and heart attack rates at one year.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT042460

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel